Navigation Links
PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
Date:6/3/2009

Adenosine Regulation with GP531 Improves the Heart's Pumping Function in Dogs with Advanced Chronic Heart Failure

NEW YORK, June 3 /PRNewswire/ -- PeriCor Therapeutics, Inc. announced today that positive preclinical results of its novel cardioprotective agent, GP531, were reported in a poster presentation by Hani N. Sabbah, Ph.D., at the European Heart Failure Congress 2009 in Nice, France. The study was funded by PeriCor Therapeutics, Inc. and conducted by Dr. Sabbah and colleagues at the Division of Cardiovascular Medicine of the Henry Ford Health System, Detroit, Michigan. GP531 is an investigational drug under development by PeriCor Therapeutics under an Investigational New Drug (IND) application.

The study entitled "Intravenous GP531, an Adenosine Regulating Agent, Improves Left Ventricular Function in Dogs with Chronic Advanced Heart Failure" found that an acute intravenous infusion of GP531 at doses ranging from 3 mcg/kg/min to 300 mcg/kg/min significantly improves left ventricular (LV) systolic function. GP531 treatment, as compared to placebo, increased ejection fraction and decreased LV end-diastolic pressure, end-diastolic volume and end-systolic volume. This improvement in the heart's pumping ability was achieved without increasing heart rate or lowering blood pressure, and GP531 did not elicit de-novo ventricular arrhythmias, even at the highest doses.

GP531 is a second generation member of a novel new class of cardioprotective compounds known as adenosine regulating agents (ARAs). ARAs, including GP531, have demonstrated impressive cardioprotective activity in preclinical models of ischemia/reperfusion injury, but this pilot study is the first to evaluate an ARA in a model of heart failure. Dr. Sabbah stated, "This encouraging preclinical study strongly supports continued preclinical and clinical exploration of GP531 as an adjunct therapy for the treatment of acute heart failure syndromes. GP531
'/>"/>

SOURCE PeriCor Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...swire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ),ab...rcializingnovelpainmanagementtherapies,announcedto...ficer,isscheduledtopresentatthe21stAnnualPiperJaff...TheNewYorkPalaceHotelinNewYork,NewYork. ,, Mr.D...llbeavailabletorespondtoquestionsduringthepresenta...
(Date:11/24/2009)...O,Nov.24/PRNewswire-FirstCall/-HamiltonThorneLtd.(...iderofadvancedlasersystemsandinstrumentsforthestem...doperationalandfinancialresultsforthethirdquartere...uewas$1.46millioncomparedwith$1.43millioninQ32008,...rcentinQ3,2008,-Netlossreducedto$148,000comparedto...
(Date:11/24/2009)...nnects Customers with Partners Validated to Proces...roducts , Ottawa, ON (PRW...provider of products for biological sample collect...d its new global partner program. The program offe...ner community and is designed to help partners sca...
(Date:11/23/2009)...ast communication, computation and more powerful w...o use quantum states as carriers of information is...s have shown, mathematically, how to gently tease ... keeping the information intact. Their work is rep...ters and highlighted with a Viewpoint in Physics...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...nstallment - From the mind to the lab bench: Rese...ology Council has published the first-ever magazi...-page publication highlights the states research b..., quality of life, key contacts and the I-Q Corrid...t. Paul. , ,The publication titled, Life Science...
... memory inside electronic devices may often be mor...n over time. , ,Now a team of scientists from the...nal Laboratory may understand why. The results are... the journal Nature Materials. , ,Smart cards, bu...all take advantage of ferroelectrics, a family of ...
...ating and advising potential angel investors, or c...eraphs was the goal of a seminar at the Entrepren... titled Private Equity and Angel Investing Boot Ca...l investing, available resources and initiatives c...choices and build networks. , ,According to State ...
Other Biology Technology:WTC launches Wisconsin Life Science magazine 2Engineers visualize electric memory as it fades 2Engineers visualize electric memory as it fades 3Angel investor boot camp advises and educates cherubs 2Angel investor boot camp advises and educates cherubs 3
(Date:11/25/2009)... Athens, Ga. Bacteria don,t have easy lives. In a...he bugs, they have natural enemies called bacterio...th every two days. , Still, bacteria and anothe...scovered in extreme environments such as deep-sea ...rt because they have a built-in defense system tha...
(Date:11/25/2009)... Over the course of a lifetime, the heart pumps so...n the order to do this, the muscle fibers of the h...oup headed by Dr. Wolfgang Rottbauer, vice chair o...versity Hospital (Chairman: Prof. Dr. H. A. Katus)... the stability of the smallest muscular unit, the ...
(Date:11/24/2009)... The Lupus Research Institute (LRI) today named 12...ng $3.6 million, recognize innovative work across ...ted for their creativity, novelty, and potential t..., treat, and cure the complex disease of systemic ...blished lupus researchers across the nation and in...
Breaking Biology News(10 mins):Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3New genetic cause of cardiac failure discovered 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Zix Corporation Addresses New HIPAA Regulations 49867 1Zix Corporation Addresses New HIPAA Regulations 49867 2Zix Corporation Addresses New HIPAA Regulations 49867 3New England Journal of Medicine Study Highlights Need for Rapid PCR based Group B Streptococcus 28GBS 29 Testing at Time of Admission for Labor and 12759 1New England Journal of Medicine Study Highlights Need for Rapid PCR based Group B Streptococcus 28GBS 29 Testing at Time of Admission for Labor and 12759 2New England Journal of Medicine Study Highlights Need for Rapid PCR based Group B Streptococcus 28GBS 29 Testing at Time of Admission for Labor and 12759 3New England Journal of Medicine Study Highlights Need for Rapid PCR based Group B Streptococcus 28GBS 29 Testing at Time of Admission for Labor and 12759 4OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX 011 wit 12758 1OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX 011 wit 12758 2OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX 011 wit 12758 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX 011 wit 12758 4OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX 011 wit 12758 5
...In studies of human brain cells, the widely-used a...sed production of amyloid-beta protein; however, w...oduce more of this Alzheimers associated protein. ...ear, and there has been concern that anesthetic us...orders. Bin Zhang, Yuanlin Dong, Rudolph Tanzi, Zh...
...Papers presented at the 1st European Lung Cancer C...ty for Medical Oncology (ESMO) and the Internation...) in Geneva, Switzerland highlight emerging eviden...opment of lung cancer. , Experts agree that smok...ibutes to lung cancer development. But other facto...
...The end of April usually brings the first signs of...r, researchers from the Woods Hole Oceanographic I...ity (NC State) are preparing for a potentially big...l seeds and excess winter precipitation have set t...historic red tide of 2005, according to researcher...
Other Biology News:Viruses may play a role in lung cancer development 2In computer models and observations, researchers see potential for significant 'red tide' season 2In computer models and observations, researchers see potential for significant 'red tide' season 3
SuperFreeze Peroxidase Conjugate Stabilizer from Pierce Biotechnology, Inc.
SA-HRP Dilution Buffer, 1L from Pierce Biotechnology, Inc.
...n optimized for the analysis of SearchLight® ...software to quickly and accurately locate and quan...or each section of a slide. SearchLight® Arra...ate standard ELISA analysis features, including cu...
...ated hybridization of microarrays on slides. The H...ffer researchers improved reproducibility, superio...orm a wide range of applications. Incubations may...up to 99C. The possibility of 6 on-board reagents ...
Biology Products: